[go: up one dir, main page]

PE20040288A1 - PHARMACEUTICAL COMPOSITIONS OF 5-METHYL-2- (2'-CHLORO-6'-FLUOROANILINO) PHENYLACETIC ACID - Google Patents

PHARMACEUTICAL COMPOSITIONS OF 5-METHYL-2- (2'-CHLORO-6'-FLUOROANILINO) PHENYLACETIC ACID

Info

Publication number
PE20040288A1
PE20040288A1 PE2003000221A PE2003000221A PE20040288A1 PE 20040288 A1 PE20040288 A1 PE 20040288A1 PE 2003000221 A PE2003000221 A PE 2003000221A PE 2003000221 A PE2003000221 A PE 2003000221A PE 20040288 A1 PE20040288 A1 PE 20040288A1
Authority
PE
Peru
Prior art keywords
chloro
methyl
fluoroanilino
pharmaceutical compositions
phenylacetic acid
Prior art date
Application number
PE2003000221A
Other languages
Spanish (es)
Inventor
Anees Abdulquadar Karnachi
Jurij Holinej
Yatindra Joshi
Maha Y Khaled
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20040288A1 publication Critical patent/PE20040288A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA PARA TRATAR UN DESORDEN O CONDICION DEPENDIENTE DE LA CICLOOXIGENASA-2, COMPRENDIDA ENTRE 200mg Y 400mg DE ACIDO 5-METIL-2-(2'-CLORO-6'-FLUOROANILINO)FENILACETICO O LUMIRACOXIB, SIENDO EL NIVEL DE HUMEDAD RESIDUAL (LOD) DE ESTA COMPOSICION ENTRE 1.5% Y 5% APROXIMADAMENTE, PUDIENDO SER TABLETAS O TABLETAS RECUBIERTAS CON PELICULAS.TAMBIEN SE REFIERE A GRANULACIONES SECAS UTILES PARA FABRICAR COMPOSICIONES CONSTITUIDO POR LUMIRACOXIB, CELULOSA MICROCRISTALINA, LACTOSA Y CROSCAMELOSA DE SODIO, DONDE EL NIVEL DE HUMEDAD RESIDUAL ES ENTRE 2.5% A 4.5% APROXIMADAMENTE U OTRAS GRANULACIONES SECAS QUE COMPRENDE LUMIRACOXIB, CROSCAMELOSA DE SODIO Y POVIDONA CON UN LOD DE 1.5% A 4% APROXIMADAMENTE.TAMBIEN SE REFIERE A UN METODO PARA ESTABILIZAR EL COMPUESTO EN UNA COMPOSICION FARMACEUTICAIT REFERS TO A SOLID PHARMACEUTICAL COMPOSITION TO TREAT A DISORDER OR CONDITION DEPENDENT ON CYCLOOXYGENASE-2, INCLUDED BETWEEN 200mg AND 400mg OF 5-METHYL-2- (2'-CHLORO-6'-FLUOROANILINE), SYNYLACETIC OR LUMINOXYLENETIC ACID LEVEL OF RESIDUAL HUMIDITY (LOD) OF THIS COMPOSITION BETWEEN 1.5% AND 5% APPROXIMATELY, MAY BE TABLETS OR TABLETS COATED WITH FILMS. ALSO REFERS TO USEFUL DRY GRANULATIONS FOR MANUFACTURING CRYSTAL LIQUID CRYSTALS AND MICROCYSTAL LIQUID COMPOSITIONS, CONSTITED LIQUID CRYSTALS WHERE THE LEVEL OF RESIDUAL HUMIDITY IS BETWEEN 2.5% TO 4.5% APPROXIMATELY OR OTHER DRY GRANULATIONS THAT INCLUDE LUMIRACOXIB, CROSCAMELLOSE SODIUM AND POVIDONE WITH A SLUDGE OF ABOUT 1.5% TO 4%. PHARMACEUTICAL COMPOSITION

PE2003000221A 2002-03-07 2003-03-06 PHARMACEUTICAL COMPOSITIONS OF 5-METHYL-2- (2'-CHLORO-6'-FLUOROANILINO) PHENYLACETIC ACID PE20040288A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36235102P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
PE20040288A1 true PE20040288A1 (en) 2004-06-24

Family

ID=27789154

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000221A PE20040288A1 (en) 2002-03-07 2003-03-06 PHARMACEUTICAL COMPOSITIONS OF 5-METHYL-2- (2'-CHLORO-6'-FLUOROANILINO) PHENYLACETIC ACID

Country Status (20)

Country Link
US (4) US20050123604A1 (en)
EP (1) EP1492520A1 (en)
JP (1) JP2005519097A (en)
KR (1) KR20040089654A (en)
CN (1) CN1330300C (en)
AR (1) AR038747A1 (en)
AU (1) AU2003227039B2 (en)
BR (1) BR0308156A (en)
CA (1) CA2476744A1 (en)
CO (1) CO5650241A2 (en)
EC (1) ECSP045244A (en)
MX (1) MXPA04008665A (en)
NO (1) NO20044164L (en)
NZ (1) NZ534587A (en)
PE (1) PE20040288A1 (en)
PL (1) PL370907A1 (en)
RU (1) RU2318497C2 (en)
TW (1) TW200305443A (en)
WO (1) WO2003074041A1 (en)
ZA (1) ZA200406226B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
EA033102B1 (en) * 2017-08-21 2019-08-30 Общество с ограниченной ответственностью "Фармамед" Pharmaceutic composition with modified delayed and sustained release containing asparaginates
WO2023113650A1 (en) * 2021-12-15 2023-06-22 Владимир Евгеньевич НЕБОЛЬСИН Pharmaceutical composition of 1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazine-2,6-dione for treating upper respiratory tract diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346525C2 (en) * 1983-12-22 1987-03-19 A. Nattermann & Cie GmbH, 5000 Köln Pharmaceutical preparation with special 1,2-diacyl-glycero-3-phosphocholines for the treatment of gastrointestinal diseases
KR100208979B1 (en) * 1992-06-12 1999-07-15 야스이 쇼사꾸 Preparations for Intra-Air Administration
JPH08511009A (en) * 1993-06-08 1996-11-19 チバ−ガイギー アクチェンゲゼルシャフト Method for producing oral solid dosage form containing diclofenac
IL126899A (en) * 1996-05-17 2004-03-28 Merck & Co Inc Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
CO4960662A1 (en) * 1997-08-28 2000-09-25 Novartis Ag CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES
DE19931708A1 (en) * 1999-07-08 2001-01-18 Bayer Ag Process for the preparation of rapidly disintegrating solid pharmaceutical preparations
AR030630A1 (en) * 2000-09-11 2003-08-27 Novartis Ag PHARMACEUTICAL COMPOSITIONS
US20030114527A1 (en) * 2001-08-31 2003-06-19 Karnachi Anees Abdulquadar Pharmaceutical composition

Also Published As

Publication number Publication date
BR0308156A (en) 2005-01-04
CA2476744A1 (en) 2003-09-12
KR20040089654A (en) 2004-10-21
AU2003227039A1 (en) 2003-09-16
US20050123604A1 (en) 2005-06-09
AR038747A1 (en) 2005-01-26
AU2003227039B9 (en) 2003-09-16
US20030171437A1 (en) 2003-09-11
ECSP045244A (en) 2004-09-28
NZ534587A (en) 2007-08-31
TW200305443A (en) 2003-11-01
PL370907A1 (en) 2005-05-30
US20090149543A1 (en) 2009-06-11
ZA200406226B (en) 2005-06-23
CO5650241A2 (en) 2006-06-30
US20070087051A1 (en) 2007-04-19
NO20044164L (en) 2004-09-30
MXPA04008665A (en) 2004-12-06
RU2004129770A (en) 2005-05-10
JP2005519097A (en) 2005-06-30
EP1492520A1 (en) 2005-01-05
CN1330300C (en) 2007-08-08
AU2003227039B2 (en) 2007-04-19
RU2318497C2 (en) 2008-03-10
WO2003074041A1 (en) 2003-09-12
CN1638752A (en) 2005-07-13

Similar Documents

Publication Publication Date Title
BR0210267A (en) Solid pharmaceutical composition, process for preparing same, obesity treatment set, composition use, obesity treatment process and lipase inhibitor
UY25322A1 (en) THIOUREA AND BENZAMIDE COMPOUNDS, COMPOSITIONS AND METHODS TO TREAT AND PREVENT INFLAMMATORY DISEASES AND ATEROSCLEROSIS
DK50487A (en) PHENOLIC THIOETHERS AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF AND ITS USE AS LIPOXYGENASE INHIBITORS
BR9806060A (en) Compound, pharmaceutical composition and processes to treat a patient suffering from a sick condition, to inhibit factor xa, and to inhibit thrombin formation.
BR9913239A (en) Extended release oral bioadhesive tablet
BR9911579A (en) Use of an antimicrobial compound for disinfection
WO2008093686A1 (en) Salt of nonsteroidal anti-inflammatory drug and organic amine compound and use thereof
PE20040972A1 (en) ACCEPTABLY NON-HYGROSCOPIC FORMULATION INTERMEDIATE INCLUDING A HYGROSCOPIC DRUG
AR011106A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DIABETES MELLITUS TYPE 2,
SV1997000026A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RHINITIS
ATE147981T1 (en) ADMINISTRATION OF LAMOTRIGINE FOR THE TREATMENT OF NEURO-AIDS
BRPI0415753A (en) method for treating and preventing respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions containing them
CO5560554A2 (en) PHARMACEUTICAL COMPOSITION INCLUDING LUMIRACOXIB
BR9910445A (en) Pharmaceutical preparation
BR9713921A (en) Compound, pharmaceutical composition, process for logician capable of being modulated through factor xa inhibition
PE20040288A1 (en) PHARMACEUTICAL COMPOSITIONS OF 5-METHYL-2- (2'-CHLORO-6'-FLUOROANILINO) PHENYLACETIC ACID
PE20020351A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING 5-METHYL-2- (2'-CHLORO-6'-FLUOROANILINE) PHENYLACETIC ACID AS INHIBITOR OF CYCLOOXYGENASE-2
NO20054408D0 (en) 3 (2-Phenyl-oxazol-4-yl-methoxy) -cyclohexylmethoxyacetic acid derivatives and similar compounds as PPAR modulators for the treatment of type 2 diabetes and arteriosclerosis
CL2004000512A1 (en) COMPOUNDS DERIVED FROM ACID 3- {1- (3- (1,3-BENZOTIAZOL-6-IL) PROPILCARBAMOIL] CYCLOALKYL} PROPANOIC, INHIBITORS OF NEUTRAL ENDOPEPTIDASE; PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM; DIABETES
CL2000002938A1 (en) Crystals of (e) -4- [4- (5-methyl-2-phenyl-4-oxazolylmethoxy) benzyloxyimino] -4-phenylbutyric acid, a pharmaceutical composition that comprises them and their use in the treatment or prevention of diabetes mellitus, hyperlipidaemia, decreased glucose tolerance, inflammatory diseases, arteriosclerosis.
PT98604A (en) PROCESS FOR THE PREPARATION OF A STABLE SODIUM HYPOCHLORITE SOLUTION
DK0701449T3 (en) Process for the preparation of an oral solid dosage form containing diclofenac
BR9707931A (en) Sulfur derivatives containing an amide bond their process of preparing their application as medicines and the pharmaceutical compositions containing them
ES2079817T3 (en) COMPOSITION FOR THE TREATMENT OF NAILS INCLUDING A SULFURATED AMINO ACID.
BRPI0414819A (en) affinity amino acid prodrugs for alpha2delta protein

Legal Events

Date Code Title Description
FC Refusal